Back to top
more

Catalyst Pharmaceuticals (CPRX)

(Real Time Quote from BATS)

$14.65 USD

14.65
344,927

-0.47 (-3.11%)

Updated Apr 25, 2024 01:37 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Spectrum Pharmaceuticals (SPPI) Gets Nod for Rolvedon Injection

by Zacks Equity Research

Spectrum Pharmaceuticals (SPPI) receives FDA approval for its drug candidate, Rolvedon (eflapergrastim), for treating chemotherapy-induced neutropenia.

Here's How Much You'd Have If You Invested $1000 in Catalyst Pharmaceutical a Decade Ago

by Zacks Equity Research

Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

Zacks.com featured highlights include Tsakos Energy, AVEO Pharmaceuticals and Catalyst Pharmaceuticals

by Zacks Equity Research

Tsakos Energy, AVEO Pharmaceuticals and Catalyst Pharmaceuticals have been highlighted in this Screen of The Week article.

Tirthankar Chakraborty headshot

Buy These 3 Top Breakout Stocks Now for Superb Returns

by Tirthankar Chakraborty

Tsakos Energy Navigation (TNP), AVEO Pharmaceuticals (AVEO) and Catalyst Pharmaceuticals (CPRX) have been selected as the breakout stocks for today.

Viracta (VIRX) Up on Orphan Drug Tag for Peripheral Lymphoma

by Zacks Equity Research

Viracta (VIRX) receives Orphan Drug designation from the European Commission for its lead candidate Nana-val for treating peripheral T-cell lymphoma. Stock up.

Catalyst (CPRX) Up 13.3% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Catalyst Pharmaceutical (CPRX) Just Reclaimed the 20-Day Moving Average

by Zacks Equity Research

Is it a good or bad thing when a stock surpasses resistance at the 20-day simple moving average?

Ironwood's (IRWD) Functional Constipation Study in Kids Succeeds

by Zacks Equity Research

Ironwood (IRWD) reports positive top-line data from a late-stage study evaluating Linzess (linaclotide) for functional constipation in pediatric patients aged six to 17 years.

Immunogen (IMGN) Provides Preliminary Data on Rare Blood Cancer Candidate

by Zacks Equity Research

Immunogen (IMGN) announces preliminary data on its CADENZA study evaluating pivekimab in blastic plasmacytoid dendritic cell neoplasm.

Pfizer (PFE), BioNTech Seek EU Nod for Omicron-Based Booster

by Zacks Equity Research

Pfizer (PFE) and BioNTech (BNTX) complete submission of conditional marketing authorization to the European Medicines Agency for Omicron BA.4/BA.5-adapted bivalent vaccine.

3 Reasons Why Catalyst (CPRX) Is a Great Growth Stock

by Zacks Equity Research

Catalyst (CPRX) could produce exceptional returns because of its solid growth attributes.

Here's Why Catalyst Pharmaceutical (CPRX) is a Great Momentum Stock to Buy

by Zacks Equity Research

Does Catalyst Pharmaceutical (CPRX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Has Aerie Pharmaceuticals (AERI) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Aerie Pharmaceuticals (AERI) and Catalyst Pharmaceutical (CPRX) have performed compared to their sector so far this year.

If You Invested $1000 in Catalyst Pharmaceutical 10 Years Ago, This Is How Much You'd Have Now

by Zacks Equity Research

Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.

Catalyst Pharmaceuticals (CPRX) Q2 Earnings Top, Revenues Up

by Zacks Equity Research

Catalyst (CPRX) beat earnings and sales estimate in second-quarter 2022 earnings. Consequently, the stock surges.

Catalyst Pharmaceutical (CPRX) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

Catalyst (CPRX) delivered earnings and revenue surprises of 17.65% and 7.75%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Kinjel Shah headshot

Drug, Biotech Stocks' Q2 Earnings on Aug 9: EXEL, BHC & More

by Kinjel Shah

Let us look at four drug and biotech companies, EXEL, BHC, CPRX and AXSM, which are gearing up for their earnings release.

Catalyst Pharmaceuticals (CPRX) Rallies 43% YTD: Here's Why

by Zacks Equity Research

Catalyst's (CPRX) price rallies on the back of the robust performance of its lead drug, Firdapse, approved for treating LEMS in adults. The company is also trying to launch Firdapse in the international markets.

Catalyst (CPRX) Stock Jumps 10%: Will It Continue to Soar?

by Zacks Equity Research

Catalyst (CPRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Catalyst (CPRX) Settles Patent Dispute Over Sole Marketed Drug

by Zacks Equity Research

Catalyst (CPRX) settles patent litigation disputes related to Firdapse, its LEMS drug. This settlement further strengthens CPRX's intellectual property hold over the drug through 2034.

    Catalyst (CPRX) Up 6.9% Since Last Earnings Report: Can It Continue?

    by Zacks Equity Research

    Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Catalyst Pharmaceuticals (CPRX) Q1 Earnings Miss, Revenues Up Y/Y

    by Zacks Equity Research

    Catalyst's (CPRX) first-quarter 2022 earnings miss estimates while revenues meet the same.

    Catalyst Pharmaceutical (CPRX) Misses Q1 Earnings and Revenue Estimates

    by Zacks Equity Research

    Catalyst (CPRX) delivered earnings and revenue surprises of -14.29% and 0.19%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

    Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Lags Revenue Estimates

    by Zacks Equity Research

    Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -13.99% and 8.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

    Kanishka Das headshot

    Drug/Biotech Stocks' Q1 Earnings on May 10: EXEL, BHC & More

    by Kanishka Das

    Let's look at the five biotech/drug companies that are slated to release quarterly results on May 10.